Evidence map›Paper›PMID 31654362›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.

Sabrina Matà, Stefano Ambrosini, Domenica Saccomanno, Tiziana Biagioli, Marinella Carpo, Aldo Amantini, Fabio Giannini, Alessandro Barilaro, Lucia Toscani, Monica Del Mastio and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Sabrina MatàDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy. masa@unifi.it.ORCID http://orcid.org/0000-0002-7034-7929
Stefano AmbrosiniDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Domenica SaccomannoDepartment of Pathophysiology and Transplantation (DEPT), Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Tiziana BiagioliGeneral Laboratory, Careggi University Hospital, Florence, Italy.
Marinella CarpoNeurology Unit, Ospedale Treviglio, Bergamo, Italy.
Aldo AmantiniDepartment NeuroMuscolar Scheletric and Sensory Organs, SOD Neurophysiology, Florence, Italy.
Fabio GianniniDepartment of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
Alessandro BarilaroDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Lucia ToscaniNeurology Unit, S.M. Annunziata Hospital, Florence, Italy.
Monica Del MastioDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Giacomo Pietro ComiDepartment of Pathophysiology and Transplantation (DEPT), Neurology Unit, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Sandro SorbiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
University of Florence · ITUniversity of Milan · ITAzienda Ospedaliera Treviglio · ITAzienda Ospedaliero-Universitaria Careggi · ITDon Carlo Gnocchi Foundation · ITOspedale SS. Annunziata · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAnti-myelin-associated glycoprotein (MAG) antibody is associated with clinically heterogeneous polyneuropathies. Our purpose was to compare neuropathy phenotypes identified by different anti-MAG tests' results.

methodsCohort study: Sera from 40 neuropathy anti-MAG EIA positive patients were tested for anti-MAG by Western blot (WB), for anti-peripheral nerve myelin (PNM) on monkey nerve by immunofluorescence assay (IFA), and for anti-HNK1 on rat CNS slices by IFA. Anti-sulfatide antibodies, for comparison, were also tested by EIA.

resultsAmong 40 anti-MAG EIA positive sera, 85% also had anti-PNM IFA reactivity and 67.5% bind HNK1 on rat CNS. Anti-HNK1 positive patients had the classical predominantly distal acquired demyelinating symmetric (DADS) neuropathy with a benign course, while anti-PNM positive but anti-HNK1 negative patients had predominantly axonal neuropathy with a high frequency of anti-sulfatide reactivity and the worst long-term prognosis. Anti-MAG EIA positive patients without anti-PNM or anti-HNK1 IFA reactivity had a CIDP-like polyneuropathy.

conclusionDifferent methods to test for anti-MAG antibodies identify different clinical and electrophysiological findings, as well as long-term outcome. HNK1 reactivity is the strongest marker of DADS.

Indexed as

AdolescentAnimalsAutoantibodiesChildChild, PreschoolFemaleHumansImmunoglobulin MMaleMyelin-Associated GlycoproteinMyelin SheathPeripheral Nervous System DiseasesPolyneuropathiesRatsYoung AdultAutoantibodiesImmunoglobulin MMyelin-Associated GlycoproteinAutoimmune diseasesChronic inflammatory demyelinating polyneuropathyEMGHNK-1Myelin-associated glycoprotein

Identifiers

PMID31654362
OpenAlexW2981896442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.